10.5061/DRYAD.QRFJ6Q5DW
Lemmerman, Luke
0000-0001-5564-5410
The Ohio State University
Balch, Maria
0000-0003-2011-6345
The Ohio State University
Moore, Jordan
The Ohio State University
Alzate-Correa, Diego
0000-0001-5750-0207
The Ohio State University
Rincon-Benavides, Maria
The Ohio State University
Salazar-Puerta, Ana
0000-0003-4954-6226
The Ohio State University
Gnyawali, Surya
0000-0001-8980-4889
The Ohio State University
Harris, Hallie
0000-0003-4819-0432
The Ohio State University
Lawrence, William
The Ohio State University
Ortega-Pineda, Lilibeth
0000-0001-9066-6719
The Ohio State University
Wilch, Lauren
Georgia Institute of Technology
Risser, Ian
0000-0001-8170-3514
The Ohio State University
Maxwell, Aidan
The Ohio State University
Duarte-Sanmiguel, Silvia
The Ohio State University
Dodd, Daniel
0000-0003-4095-053X
The Ohio State University
Guio-Vega, Gina
National University of Colombia
McTigue, Dana
0000-0001-7066-9701
The Ohio State University
Arnold, William
The Ohio State University
Nimjee, Shahid
0000-0002-0317-8731
The Ohio State University
Sen, Chandan
Indiana University
Khanna, Savita
Indiana University
Rink, Cameron
The Ohio State University
Higuita-Castro, Natalia
The Ohio State University
Gallego-Perez, Daniel
0000-0002-6263-3191
The Ohio State University
Data from: Nanotransfection-based vasculogenic cell reprogramming drives
functional recovery in a mouse model of ischemic stroke
Dryad
dataset
2021
FOS: Medical engineering
National Institute on Aging
https://ror.org/049v75w11
DP2EB028110
National Institute of Neurological Disorders and Stroke
https://ror.org/01s5ya894
R21NS099869
National Cancer Institute
https://ror.org/040gcmg81
P30-NS045758
National Institute of Neurological Disorders and Stroke
https://ror.org/01s5ya894
R01NS085272
National Institute of Neurological Disorders and Stroke
https://ror.org/01s5ya894
R01NS042617
2021-01-25T00:00:00Z
2021-01-25T00:00:00Z
en
56808 bytes
2
CC0 1.0 Universal (CC0 1.0) Public Domain Dedication
Ischemic stroke causes vascular and neuronal tissue deficiencies that
could lead to significant functional impairment and/or death. Although
progenitor-based vasculogenic cell therapies have shown promise as a
potential rescue strategy following ischemic stroke, current approaches
face major hurdles. Here we used fibroblasts nanotransfected with Etv2,
Foxc2, and Fli1 (EFF), to drive reprogramming-based vasculogenesis,
intracranially, as a potential therapy for ischemic stroke. Perfusion
analyses suggest that intracranial delivery of EFF-nanotransfected
fibroblasts led to a dose-dependent increase in perfusion 14 days
post-injection. MRI and behavioral tests revealed ~70% infarct resolution
and up to ~90% motor recovery for mice treated with EFF-nanotransfected
fibroblasts. Immunohistological analysis confirmed increases in
vascularity and neuronal cellularity, as well as reduced glial scar
formation in response to treatment with EFF-nanotransfected fibroblasts.
Altogether, our results suggest that vasculogenic cell therapies based on
nanotransfection-driven (i.e., non-viral) cellular reprogramming represent
a promising strategy for the treatment of ischemic stroke.